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Abstract
Histone deacetylases (HDACs) are known to play a central role in the regulation of several cellular properties interlinked with
the development and progression of cancer. Recently, HDAC1 has been reported to be overexpressed in hepatocellular
carcinoma (HCC), but its biological roles in hepatocarcinogenesis remain to be elucidated. In this study, we demonstrated
overexpression of HDAC1 in a subset of human HCCs and liver cancer cell lines. HDAC1 inactivation resulted in regression of
tumor cell growth and activation of caspase-independent autophagic cell death, via LC3B-II activation pathway in Hep3B
cells. In cell cycle regulation, HDAC1 inactivation selectively induced both p21
WAF1/Cip1 and p27
Kip1 expressions, and
simultaneously suppressed the expression of cyclin D1 and CDK2. Consequently, HDAC1 inactivation led to the
hypophosphorylation of pRb in G1/S transition, and thereby inactivated E2F/DP1 transcription activity. In addition, we
demonstrated that HDAC1 suppresses p21
WAF1/Cip1 transcriptional activity through Sp1-binding sites in the p21
WAF1/Cip1
promoter. Furthermore, sustained suppression of HDAC1 attenuated in vitro colony formation and in vivo tumor growth in a
mouse xenograft model. Taken together, we suggest the aberrant regulation of HDAC1 in HCC and its epigenetic regulation
of gene transcription of autophagy and cell cycle components. Overexpression of HDAC1 may play a pivotal role through
the systemic regulation of mitotic effectors in the development of HCC, providing a particularly relevant potential target in
cancer therapy.
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Introduction
Hepatocellular carcinoma (HCC) is a primary malignancy of
human liver and a major cause of morbidity and mortality. It is the
seventh most common cancer worldwide, and the third leading
cause of cancer-related deaths [1]. In the molecular mechanism,
hepatocarcinogenesis is accepted as a multistep process charac-
terized by the progressive accumulation and interplay of genetic
alterations causing aberrant growth and malignant transformation
of liver parenchymal cells, followed by vascular invasion and
metastasis [2]. The global change signatures of the gene expression
and signaling pathways, involved in HCC development, were
investigated by many researchers. However, numerous genes
which contribute to these alterations are still not characterized
sufficiently.
Histone deacetylases (HDACs) are histone modifying enzyme
families that regulate the expression and activity of numerous
proteins involved in both cancer initiation and progression, by
removing the acetyl groups, and thus allowing compact chromatin
structure [3]. HDACs comprise a family of 18 genes, which are
grouped into classes I-IV based on the homology to their
respective yeast orthologues [4]. HDAC1, as a class I member
sharing a high sequence homology with yeast Rpd3, is a global
gene regulator and transcriptional co-repressor with histone
deacetylase activity [5]. Aberrant expression of HDAC1 appears
common in cancers of the gastrointestinal system, and is associated
with dedifferentiation, enhanced proliferation, invasion, advanced
disease and poor prognosis [4]. HCC patients with high expression
of HDAC1 showed higher incidence of cancer cell invasion into
the portal vein, poorer histological differentiation, more advanced
tumor-node-metastasis (TNM) stage and low survival rate [6]. It
was also found that highly expression of HDAC1 in cancer cells is
correlated with chemotherapy resistance and poor prognosis in a
series of carcinomas [7,8,9]. Silence of HDAC1 by small
interference RNA (siRNA) or specific inhibitor MS-275 in cancer
cells can either arrest at the G1 phase of the cell cycle or at the
G2/M transition, resulting in the loss of mitotic cells, cell growth
inhibition, and increase in the percentage of apoptotic cells
[10,11,12]. In addition, HDAC1 knockdown affected cell motility
and invasion by regulating E-cadherin expression [13,14], and was
also shown to induce autophagy in Hela cells [15], and cellular
senescence in human fibroblast cells and prostate cancer cells [16].
Although these molecular functions of HDAC1 were well
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hepatocarcinogenesis has not been elucidated.
In the present study, in order to investigate the biological roles
of HDAC1 that confer oncogenic potential in human HCC, we
assessed the aberrant regulation of HDAC1 in a subset of human
HCC tissues and examined the regulatory mechanisms of HDAC1
in apoptosis, autophagy and cell cycle of HCC cells. In addition, in
vitro and in vivo experimental tumorigenic potential of HDAC1
were explored using stable HDAC1 knockdown cell lines.
Results
HDAC1 suppression causes mitotic defects in HCC cells
We previously reported large-scale transcriptomic changes from
preneoplastic lesion to overt human HCCs [17]. From primary
microarray data, we recapitulated the expression of HDAC1 in a
multi-step histopathological process, from low-grade dysplastic
nodules (LGDNs) and high-grade dysplastic nodules (HGDNs) to
primary HCC (Edmondson grades 1–3). As shown in Figure 1A,
the relevant expression of HDAC1 was gradually increased from
non-tumor to overt cancer. To confirm the overexpression of
HDAC1 in HCC, we performed immunoblot analysis of HDAC1
in a subset of human HCCs. As shown in Figure 1B, HDAC1
appeared to be highly overexpressed in all selected HCC tissues
compared to the corresponding non-cancerous tissues. Expression
of HDAC1 was also analyzed in ten different HCC cell lines
(HepG2, Hep3B, PLC/PRF/5, SNU182, SNU354, SNU368,
SNU387, SNU423, SNU449 and SNU475) and compared with
three selective immortalized normal liver hepatocyte cell lines
(THLE-2, THLE-3 and MIHA). As shown in Figure 1C,
endogenous expression of HDAC1 in all HCC cell lines exhibited
relatively higher than that of normal liver hepatocyte cell lines.
Next, to explain the biological consequences of aberrant
expression of HDAC1 in hepatocarcinogenesis, HDAC1 expres-
sion was abrogated by the RNA-interference mediated gene
knock-down in four different HCC cell lines; HepG2, Hep3B,
SNU182 and SNU449 cells. As shown in Figure 1D, HDAC1
depletion resulted in the significant reduction of tumor cell growth
(HepG2, Hep3B and SNU449). This anti-growth effect could be
partially explained by the disruption of cell growth regulation,
such as cell cycle arrest, cellular senescence or apoptosis. Thus, we
next explored the effects of HDAC1 suppression on the cell cycle
regulation and cellular apoptosis.
Aberrant expression of HDAC1 mediated proliferation of
liver cancer cells by deregulating expression of G1/S cell
cycle proteins
The fact that the suppression of HDAC1 caused regression of
liver cancer cell growth implies that HDAC1 is involved in the
regulation of the cell cycle progression. Thus, we performed cell
cycle analysis of PI-stained cells in HDAC1 siRNA transfectants
using flow cytometry. HDAC1 depletion led to an increase in G1
phase by 17.0% with a concomitant decrease in S phase and G2/
M phase by 1.1% and 15.9%, respectively compared to the control
(si-Scr) at 48 h after transfection (Figure 2A). The fact that the
suppression of HDAC1 caused cell cycle arrest in G1 phase
implies that HDAC1 can modulate activities of cell cycle
regulating components. Therefore, we examined the effects of
HDAC1 depletion on the regulatory proteins of G1/S cell cycle
transition. In G1/S transition, it has been well established that
negative cell cycle regulators, such as p15
INK4B, p16
INK4A,
p18
INK4C, p19
INK4D, p21
WAF1/Cip1 and p27
Kip1, are the key
modulators that suppress cyclin D1/CDK4 and 6, or cyclin E/
CDK2 complexes. When these cell cycle modulators were
examined, HDAC1 depletion selectively caused the induction of
p21
WAF1/Cip1 and p27
Kip1 among the negative regulators of cell
cycle transition in Hep3B cells (Figure 2B). Notably HDAC1
inactivation by using HDAC1 siRNA did not affect endogenous
expression of HDAC2, and it also caused accumulation of
acetylated histone H3 and H4 implying HDAC1 depletion-
specific induction of p21
WAF1/Cip1 and p27
Kip1 in Hep3B cells. In
addition, HDAC1 depletion also elicited the concomitant
suppression of CDK2 and cyclin D1 (Figure 2C). In general, the
activated CDK/cyclin complex can cause hyperphosphorylation
of pRb, which loses its tumor suppressor activity, and which allows
for the increase of E2F/DP1 transcriptional activity. Thus, we
next investigated whether dysregulation of CDK and cyclins by
HDAC1 affects the E2F/DP1 transcriptional activity in Hep3B
cells. Targeted-disruption of HDAC1 elicited hypophosphoryla-
tion of p130, a pRb isoform (Rb2). Consequently, some of the
downstream target genes of E2F/DP1 transcription factor, such as
E2F4, CDC2 and cyclin A, were significantly down-regulated
(Figure 2D). Further, to validate these results and to confirm
transcriptional levels of differentially expressed genes, we per-
formed quantitative real-time PCR (qRT-PCR) for HDAC1,
CDKN1A (p21
WAF1/Cip1), CDKN1B (p27
Kip1), CDK2 and CCND1
(cyclin D1) genes. As shown in Figure 2E, HDAC1-depleted
Hep3B cells exhibited very low endogenous HDAC1 expression.
We were also able to confirm that both CDKN1A (p21
WAF1/Cip1)
and CDKN1B (p27
Kip1) were significantly up-regulated by HDAC1
inactivation. Inversely, CDK2 and CCND1 were appeared to be
down-regulated by HDAC1 inactivation (Figure 2E). These results
suggest that exclusive regulation of cell cycle proteins, such as
p21
WAF1/Cip1, p27
Kip1, cyclin D1 and CDK2 by HDAC1
overexpression exerts a very potent mitogenic stimulation during
liver cancer progression.
Several studies have shown that HDAC inhibitors strongly
activate the expression of p21
WAF1/Cip1 through enhanced histone
acetylation of the p21
WAF1/Cip1 promoter including Sp1- binding
site by releasing the repressor HDAC from its binding [18,19].
Furthermore, there were some evidences that the endogenous
expression of p21
WAF1/Cip1 is regulated at the transcription level
by the recruitment of HDAC1 to the p21
WAF1/Cip1 promoter
region [20,21]. Our present results also suggest that the
transcriptional suppression of p21
WAF1/Cip1 through HDAC1
binding on its promoter region is predominant in liver cancer
cells. To validate this implication, we performed chromatin
immunoprecipitation assay with quantitative PCR (ChIP-qPCR)
for indicated p21
WAF1/Cip1 promoter regions which had been
analyzed in our previous report (Figure 3A) [22]. We found that
HDAC1 is highly associated with the proximal region of the
p21
WAF1/Cip1 promoter (region D in Figure 3B). This result was
further validated by ChIP-qPCR analysis with the same promoter
region of p21
WAF1/Cip1 (region D), and which showed that the
acetylation status of histone H3 and/or H4 is enhanced on the
genomic locus by the abrogation of HDAC1 (Figure 3C).
As described above, there are enriched Sp1-biding sites in
region D. So, we next investigated whether HDAC1 suppresses
p21
WAF1/Cip1 expression via Sp1-binding sites on the p21
WAF1/Cip1
promoter. To confirm this, we performed the reporter assay with
reporterconstructsdescribed inmaterialsandmethods. Asshownin
Figure 3D, HDAC1-deficient Hep3B cells (si-HDAC1) exhibited
increased luciferase activity in the presence of Sp1-binding sites, at
least containing Sp1-3 to Sp1-6 (pWWP, pWPdel-BstXI and
pWP101). However, p21
WAF1/Cip1 transcription activity was not
induced by mutant forms of Sp1-5,6 (pWPmt-Sp1-5,6) in si-
HDAC1 cells. Interestingly, p21
WAF1/Cip1 transcription was still
induced by two mutant plasmids (i.e. pWPdel-SmaI and Sp1-luc)
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TATA box or transcription start site. This result indicates that the
proximal region around the TATA box of p21
WAF1/Cip1 promoter
is expected to be an important site regulating p21
WAF1/Cip1
transcription by HDAC1 in Hep3B cells.
Targeted-inhibition of HDAC1 induces autophagic cell
death of Hep3B cells
Recent studies suggested that the treatment with histone
deacetylase inhibitors induced not only apoptotic, but also
autophagic cell death [23,24,25]. It was also found that
knockdown of HDAC1 induces autophagic cell death in Hela
cells [15]. Thus, we explored the effects of HDAC1 suppression on
the activation of cell death in Hep3B cells. As shown in Figure 4A,
flow cytometric analysis for measuring Annexin V stained cells
showed no significant induction of apoptotic cells compared to
control (si-Scr). Additionally, HDAC1 depletion did not affect the
expressions of pro-apoptotic components, such as AIF, Bax and
Apaf-1, nor did it cause caspase-3 and PARP cleavage (Figure 4B).
These results indicated that overexpression of HDAC1 did not
mainly affect the apoptotic signal in HCC.
Next, to determine whether HDAC1 inactivation causes
activation of autophagic cell death, we examined the microscopic
structure of cells by transmission electron microscopy (TEM) in
HDAC1-depleted Hep3B cells. As expected, approximately 40–
45% of the HDAC1 siRNA-transfected cells developed autophagic
vacuoles after 72 h of post-transfection (Figure 5A). At higher
magnifications, most vacuoles contained electron dense material
and degraded organelles. In contrast, control siRNA (si-Scr)
transfected-cells were merely vacuolated, and fewer cells contain-
ing vacuoles in cytoplasm were observed (right two panels in
Figure 5A). Microtubule-associated protein 1 light chain 3 (LC3) is
a common marker for detecting autophagy. LC3 is post-
translationally modified by removal of its C-terminus to produce
LC3-I (,18 kDa), with phosphatidylethanolamine lipidation
giving rise to LC3-II (,16 kDa). Enrichment of membrane-bound
LC3-II in autophagosomes is a distinctive phenomenon of
autophagic cell death and the amount of LC3-II correlates well
with the number of autophagosomes. In our experiments, HDAC1
knockdown significantly increased the conversion of LC3B-I into
LC3B-II as much as ceramide, a potent autophgy inducer, did in
Hep3B cells (Figure 5B). In contrast, treatment with 3-methyla-
denine (3-MA; a specific inhibitor of autophagy) prevented LC3B-
I to LC3B-II conversion by HDAC1 inactivation in Hep3B cells
(lane 5 in Figure 5B). In addition, immunofluorescence staining for
LC3B revealed that HDAC1 inactivation induced ring-shaped
spots evenly distributed throughout cytoplasm, indicating an
association between LC3 and autophagosomal membranes, and
this association was significantly blocked by 3-MA treatment
(Figure 5C). Consistent with this result, reduced cell viability
caused by HDAC1 inactivation was effectively blocked by 3-MA
treatment (Figure 5D). These results suggest that the HDAC1
knockdown activates autophagic cell death in HCC cells.
Interestingly, we also found that HDAC1 inactivation did not
affect Beclin-1 which participates during the early stages of
autophagy, and that it promotes the nucleation of autophagic
vesicles, and the recruitment of proteins from cytosol [26]. This
implicated that HDAC1 inactivation induced Beclin-1 indepen-
dent autophay in Hep3B cells. To verify that HDAC1 inactivation
mediates LC3B-dependent autophagic cell death, LC3B was
silenced in Hep3B cells. As shown in Figure 5E, LC3B-II
conversion induced by HDAC1 inactivation was completely
blocked by LC3B knockdown in Hep3B cells. Further, the
decreased cell viability by HDAC1 inactivation was significantly
restored by the co-transfection of LC3B siRNA in Hep3B cells
(Figure 5F). Collectively, these results suggest that HDAC1
inactivation contributes caspase-independent cell death through
LC3-dependent autophagy in Hep3B cells.
Sustained-suppression of HDAC1 attenuates tumorigenic
potential of Hep3B cells both in vitro and in vivo
Our results showed that the transient disruption of HDAC1
caused in vitro autophagic cell death and growth arrest in Hep3B
cells. Thus, to investigate whether the stable suppression of
HDAC1 leads to suppression of hepatocarcinogenesis, we
established stable HDAC1 knockdown cell lines (HDAC1KD#1
and HDAC1KD#2), and confirmed the inactivation of HDAC1
by detecting p21
WAF1/Cip1 and p27
Kip1 induction and CDC2
reduction in established cell lines (Figure 6A). We then assessed the
growth rate of the established cell lines. As shown in Figure 6B,
HDAC1KD#1 cells exhibited reduced growth rate, as compared
to either Mock-transfectant (Mock#1) or Hep3B parental cells
(None). Based on this result, we next performed the colony
forming assay as described in materials and methods. The clonal
cell growth was significantly attenuated by the sustained
suppression of HDAC1 in HDAC1KD#1 cells, as compared to
the control (Mock#1) (Figure 6C, p,0.05). Finally, to demon-
strate that HDAC1 overexpression contributes to hepatocarcino-
genesis in vivo, we subcutaneously injected established cell lines (i.e.
HDAC1KD#1 or Mock#1) into athymic nude mice. The overall
tumor growth rate and volume were significantly reduced in
HDAC1 deficient cell line (HDAC1KD#1) compared to the
control (Mock#1) (Figure 6D, p,0.05). At 37 days post-
inoculation, tumor mass was detectable in the Mock group. In
contrast, in the mice that were injected with HDAC1KD#1,
tumor mass was detectable only at 48 days post-inoculation. The
average tumor volume at sacrifice was much smaller in the group
injected with HDAC1KD#1 than Mock#1 cells (Figure 6E,
p,0.05). In addition, immunoblot analysis revealed that the
expressions of p21
WAF1/Cip1, p27
Kip1 and LC3B-II were signifi-
cantly induced in HDAC1 deficient xenograft tissues (Figure 6F,
p,0.05). These results imply that the suppression of HDAC1
contributes to the inhibition of hepatocarcinogenesis in vivo.
Discussion
Histone deacetylases (HDACs) represent a family of enzymes
that cooperate with histone acetyltransferase to modulate
chromatin structure and transcriptional activity via changes in
the acetylation status of nucleosomal histones [27]. Accumulating
evidences have suggested that HDACs regulate both the
Figure 1. Aberrant expression of HDAC1 in human HCCs and liver cancer cell lines. (A) HDAC1 mRNA expression shows gradual increase
from pre-cancer to the overt HCCs (*p,0.05). LGDN, low-grade dysplastic nodule; HGDN, high-grade dysplastic nodule; G1–3, Edmondson grades 1–
3. (B) Ten pairs of tumor (T) and their corresponding non-tumor (N) liver tissues were obtained from surgical resections. The protein level of HDAC1
was assessed by Western blot analysis. (C) The endogenous levels of HDAC1 in ten liver cancer and three normal cell lines. An antibody against
GAPDH served as loading control. (D) Targeted-disruption of HDAC1 causes the growth retardation of HCC cell lines. Cell viability was determined by
MTT assay in the indicated cell lines transfected with either scramble (si-Scr) or HDAC1 siRNA (si-HDAC1). Data were expressed as mean 6 SD
(*p,0.01). All measurements were performed in triplicate, and each experiment was repeated at least two times.
doi:10.1371/journal.pone.0034265.g001
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34265Figure 2. HDAC1 controls the expressions of regulatory components in G1/S cell cycle transition. Hep3B cells were transfected with
control (None), lipofectamine only (Reag), 100 nmol/L scrambled siRNA (si-Scr) or 100 nmol/L of HDAC1-specific siRNA (si-HDAC1). (A) The flow
cytometric analysis was conducted with propidium iodide (PI) staining on suppression of HDAC1 in Hep3B cells. Two independent experiments with
the same results were performed. (B) To ascertain the suppression of HDAC1 activity, protein expressions of acetyl-histone H3 and H4 were
determined by immunoblotting. Protein expressions of negative regulators in G1/S cell cycle transition were also assessed in HDAC1-depleted Hep3B
cells. (C) Suppression of CDKs and cyclins in G1/S transition by HDAC1 depletion. (D) Effects of HDAC1 depletion on pRb and E2F/DP1 target gene
expressions. (E) Validation of the mRNA expression of HDAC1 regulated genes by quantitative real-time PCR analysis. The relative expression level of
each gene was normalized to GAPDH mRNA in the same sample. Protein expression level was quantified by ImageJ and normalized to GAPDH. The
values are given as fold-change relative to the si-Scr tansfectants. The relative proteins level is shown as bar graphs in right side of each immunoblot
(*p,0.05). All experiments were repeated three times with the same results. A typical result of three performed experiments is shown.
doi:10.1371/journal.pone.0034265.g002
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WAF1/Cip1 transcription via Sp1-binding sites in the p21
WAF1/Cip1 promoter. (A) A schematic of the
p21
WAF1/Cip1 promoter depicting the regions analyzed by ChIP-qPCR (black bars, A–D). (B) The association of HDAC1 in the p21
WAF1/Cip1 promoter was
assessed by the amplification of each region immunoprecipitated with HDAC1. The amount of DNA precipitated by either anti-HDAC1 or control IgG
was expressed as percentage of the total input genomic DNA. The result of four independent experiments was shown as mean 6 SD. (C) Acetylations
of histone H3 and H4 associated with the proximal p21
WAF1/Cip1 promoter was increased by inhibiting association of HDAC1. Hep3B cells were
transiently transfected with control (si-Scr) or HDAC1 siRNA (si-HDAC1) for 48 h, and subjected to ChIP-qPCR analysis using acetyl-histone H3 (anti-Ac-
H3) or H4 (anti-Ac-H4) antibody or control IgG. Precipitated genomic DNA was amplified for the proximal promoter of the p21
WAF1/Cip1 locus (region
D) by real-time PCR. The amount of precipitated DNA was expressed as percentage of the total input genomic DNA. The result of three independent
experiments was shown as mean 6 SD. (D) HDAC1 regulates p21
WAF1/Cip1 transcription via Sp1-binding sites in the p21
WAF/Cip1 promoter. The
indicated constructs, pWWP, pWPdel-BstXI, pWP101, pWPmt-Sp1-3, pWPmt-Sp1-5,6, pWPdel-SmaI and Sp1-luc were transiently transfected into
Hep3B cells, with 100 nmol/L scrambled siRNA (si-Scr) or 100 nmol/L HDAC1 specific siRNA (si-HDAC1), respectively. The promoter activity was
measured, and fold induction by HDAC1 depletion was calculated. On the left, the scheme of each construct was shown. All the data were shown as
the mean 6 SD (n=3) (*p,0.05).
doi:10.1371/journal.pone.0034265.g003
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cancer initiation and progression [27,28]. Recently, several studies
have shown that certain HDAC families are aberrantly expressed
in tumors and have redundant function in cancer development
[4,29]. Consistently, increasing evidence suggested the aberrant
expression of HDAC1 in neoplastic diseases, and demonstrated
that HDAC1 depletion causes growth arrest and apoptosis of
certain human cancer cells [10,27,29]. However, the role of
HDAC1 in hepatocarcinogenesis has not been elucidated yet. In
this study, we have suggested that the abrogation of aberrant
expression of HDAC1 activated the caspase-independent autoph-
agic cell death and arrested the G1/S cell cycle transition in
human Hep3B cells, and consequently suppressed the tumor cell
growth in the xenograft animal model.
In a recent study of gastric cancer, HDAC1 expression was
reported to be overexpressed and had prognostic value for gastric
cancer [8]. Induction of HDAC1, 2, 3 expression levels also
implicated significantly reduced patient survival in colorectal
cancer [30]. The contribution of the HDAC1 expression to the
malignant transformation of normal liver was also studied in a
transgenic mouse model [31]. Furthermore, a recent report
suggested that both HDAC1 and HDAC2 cooperatively regulated
the proliferation of mouse embryonic fibroblast (MEF) and had an
essential role for the hematopoietic differentiation [32]. In
hepatocellular carcinoma, high HDAC1 expression was associated
with cancer cell invasion into the portal vein, poor histological
differentiation and low patient survival [6]. This was also
confirmed by our previously published comprehensive mRNA-
based expression microarray data [17]. Of these outlier genes
associated with multi-step hepatocarcinogenesis, we recapitulated
HDAC1 expression and showed highly overexpression in overt
HCC. Immunoblot analysis of HDAC1 in a subset of human
HCC tissues and liver cancer cell lines demonstrated overexpres-
sion of HDAC1 in HCCs, and targeted-disruptions of HDAC1
caused growth retardation in various HCC cell lines (Figure 1).
The accumulating evidences suggest that HDAC1 overexpression
appears especially common in cancers of the gastrointestinal
system and is associated with dedifferentiation, enhanced prolif-
eration, invasion, advanced disease and poor prognosis. However,
no attempt has been made to explain the underlying mechanisms
responsible for the oncogenic potential of HDAC1 in HCC. We
therefore assessed effects of HDAC1 inactivation on the regulatory
proteins in the cell growth and death mechanism.
It has been well reported that HDAC-mediated repression of
genes can cause uncontrolled cell growth, as HDACs repress the
transcription of cyclin-dependent kinase inhibitors (CDKIs),
allowing continued proliferation [27]. In osteosarcoma and breast
cancer cells, it was reported that the knockdown of HDAC1
resulted in the cell cycle arrest either at the G1 or G2/M phase
transition, and increased the percentage of apoptotic cells [10].
Figure 4. HDAC1 inactivation does not induce apoptotic cell death in Hep3B cells. (A) The flow cytometric analysis was conducted through
Annexin V-FITC labeling and PI staining on suppression of HDAC1. Double staining with Annexin V-FITC and PI indicates that the amount of cells in
the late stage of apoptosis was slightly increased (Upper right) in HDAC1-depleted Hep3B cells. Two independent experiments with the same results
were performed. (B) Both PARP and caspase 3 cleavage were not detected by HDAC1 inhibition. All experiments were repeated three times with the
same results.
doi:10.1371/journal.pone.0034265.g004
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p21
WAF1/Cip1 and p27
Kip1 expressions thereby implying the
inhibition of G1/S transition of cell cycle (Figure 2B). In addition,
HDAC1 knockdown suppressed the expression of cyclin D1 and
CDK2 (Figure 2C). Although it is not clear whether HDAC1
suppresses the cyclin D1 and CDK2 directly or through the
induction of p21
WAF1/Cip1, it is obvious that this synergistic
negative regulation of G1/S transition suggests a potent role of
HDAC1 in cell cycle regulation. Orderly progression through the
cell cycle checkpoints involves coordinated activation of the
CDKs, in the presence of an associated CDK-activating kinase, by
phosphorylating the target substrates including members of the
‘‘pocket protein’’ family. One of these, the product of the
retinoblastoma susceptibility gene (the pRb protein) is phosphor-
ylated sequentially by the kinase activities of CDK4/cyclin D1 and
CDK2/cyclin E complexes. Our results also demonstrated that the
resulting suppression of CDK/cyclin complex augmented the
hypophosphorylation status of p130, an isoform of pRb (Rb2), and
suppressed transcriptional activation of E2F/DP1 target genes
(Figure 2D).
HDACs were known to function by interacting with the tumor
suppressor genes such as p53, pRb and BRCA1 [33,34,35]. For
example, HDAC1 is necessary for the repression of E2F target
genes by the interaction with pRb [33]. Alternatively, the
deacetylation of non-histone proteins, such as p53, may also play
a role in controlling the cell cycle dynamics. Unlike this suppressor
role of HDAC1 on pRb and its interaction with E2F/DP
transcription, our data suggests that HDAC1 acts as a potent
modulator, suppressing the expression level of CDK inhibitor and
augmenting cyclins and CDKs of the cell cycle circuit, especially in
the G1/S transition in HCC. In addition, our results also
demonstrated that the suppression of HDAC1 induces p21
WAF1/Cip1
via Sp1-binding site of its promoter region in a p53-independent
manner (Hep3B is a p53-null cell line). Although it is not clear that
HDAC1 directly suppresses p21
WAF1/Cip1 through Sp1-binding site
or does so indirectly by forming a complex with other molecules, it is
obvious that HDAC1 suppression causes its release from the Sp1-
binding site around the TATA box (Sp1-5,6), which leads to the
enrichment of acetylated histones at the proximal region of the
p21
WAF1/Cip1 promoter (Figure 3).
Interestingly, unlike previous studies demonstrating the increase
of apoptosis by HDAC1 inhibition, our results indicated that
HDAC1 inactivation did not induce apoptosis (Figure 4) in liver
cancer. Recently, HDAC1 inactivation was shown to induce
autophagy in Hela cells [15]. With the TEM analysis for
investigating microscopic structure of the cells with HDAC1
depletion, we could expect that HDAC1 suppresses the formation
of autophagosome, which leads to the inhibition of autophagic cell
death in HCC cells (Figure 5A). Further, we found that a part of
autophagic cell death was modulated by HDAC1 through the
activation of LC3 conversion (LC3-I to LC3-II) (Figures 5B–F).
Given the inherent resistance to apoptosis that characterizes
cancer, the targeting of alternative pathways is an attractive
strategy to improve anti-tumor therapy. Our data showed that
HDAC1 suppresses both cell cycle arrest and caspase-independent
autophagic cell death in liver cancer cells. Therefore, these
suppressive roles of HDAC1 may confer the effective oncogenic
potential upon the cells, which increases the transforming activity
during hepatocarcinogenesis.
In conclusion, we have shown the aberrant expression of
HDAC1 in human HCC. We have also demonstrated that the
targeted disruption of HDAC1 led to the strong anti-proliferative
effect and induced autophagic cell death in HCC. Detailed
analyses of the molecular mechanisms governing gene regulation
by HDAC1 will illustrate how this protein influences proliferation
and autophagic cells death. From those interpretations, we derived
a conclusion that the aberrant actions of HDAC1 disturbed
homeostasis via dysregulation of autophagy and cell cycle signaling
in hepatocytes. Taken together, our present results underlined the
tremendous potential of HDAC1 for enhancing our understanding
of the intricate mechanisms of cell death as well as mitogenic
stimulation of liver cells in the development of HCC, thereby
suggesting HDAC1 as a novel target for therapeutic intervention.
Materials and Methods
Ethics Statement
Total ten hepatocellular carcinoma tissues with their corre-
sponding normal were obtained from Yonsei University, School of
Medicine, Seoul, Korea. Informed consent form was provided
according to the Declaration of Helsinki. This study was approved
by Institutional Review of Board of the Songeui Campus, College
of Medicine, The Catholic University of Korea (IRB approval
number; CUMC10U036). For the animal study, all animal
experiments were performed with the approval of the Institutional
Animal Care and Use Committee (IACUC) of Department of
Laboratory Animal, College of Medicine, The Catholic University
of Korea (approval number; CUMC-2009-0050-03).
Cell culture and transfection
THLE-2 and THLE-3 (ATCC, Bethesda, MD, USA), which
were derived from human primary normal liver cells, were
cultured in Bronchial Epithelium Basal Medium (BEBM) (Lonza,
Walkersville, MD, USA) supplemented with 10% fetal bovine
serum (FBS) (Invitrogen, Carlsbad, CA, USA), 5 ng/mL epider-
mal growth factor (EGF) and 70 ng/mL phosphoethanolamine.
Another normal liver hepatocyte, MIHA (kindly provided by Dr.
Jayanta Roy-Chowdhury) was maintained in DMEM supplement-
ed with 10% FBS, penicillin (100 U/mL) and streptomycin
(100 mg/mL). Ten human HCC-derived cell lines; HepG2,
Figure 5. HDAC1 inactivation causes autophagic cell death in Hep3B cells. (A) Hep3B cells were transfected with HDAC1 siRNA (100 nmol/L)
for 72 h, fixed and reviewed under the transmission electron microscope (TEM) (left two panels). With a higher magnification, autophagosomes
containing electron dense material and degraded organelles were observed in HDAC1-deficient cells. In contrast, a lot of intact mitochondria were
observed in Hep3B cells transfected by si-Scr (right two panels). Arrows indicate the presence of autophagosomes. (B) After knockdown of HDAC1,
LC3 conversion (LC3B-I to LC3B-II) was markedly increased, whereas the level of Beclin 1 did not change. Parallel treatment with 5 mM 3-MA for 48 h
inhibited LC3B-II activation induced by HDAC1 knockdown. Hep3B cells were also treated with 25 mM ceramide for 24 h as a positive control for the
autophagy. The densitometry result of the immunoblots was shown as a bar graph (mean 6 SD). Relative protein expressions of HDAC1, LC3B-II and
Beclin 1 were normalized with the expression level of control (si-Scr) (*p,0.05). (C) In the immunofluorescence analysis, the cytosolic expression of
LC3B was induced by HDAC1 knockdown, and which was reversed by the treatment with 3-MA in Hep3B cells. (D) MTT analysis shows that cell
viability was regressed by HDAC1 knockdown in Hep3B cell. The number of viable cells was increased in the parallel treatment of 3-MA for 48 h
(*p,0.05). (E) Co-transfection of siRNA targeting LC3B and/or HDAC1. The LC3B conversion was induced by si-HDAC1 in the absence of si-LC3B. The
level of proteins were quantified by ImageJ and normalized to GAPDH. Bar graph shows the relative ratio to si-Con transfectant (*p,0.05). (F) MTT
analysis shows that the cells viability was recovered apparently in the presence of si-LC3B in HDAC1 knockdown Hep3B cells (*p,0.05, si-HDAC1+si-
LC3B vs si-HDAC1).
doi:10.1371/journal.pone.0034265.g005
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e34265Figure 6. Sustained suppression of HDAC1 abrogates the tumorigenic potential of Hep3B cells. (A) The confirmation of HDAC1
suppression by detecting its specific target genes in cell cycle regulation. A typical result of three independent experiments was shown. The protein
expressions were quantified and normalized to GAPDH, and were shown as relative ratio to Mock. (B) Cell growth rate of Hep3B cells stably
expressing a scrambled shRNA (Mock#1) or HDAC1 shRNA (HDAC1KD#1) was determined by counting assay at each indicated time point. Data were
presented as mean 6 SD for three experiments. (C) In vitro colony formation assay. Cell clones expressing scrambled shRNA (Mock#1) or HDAC1
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SNU423, SNU449 and SNU475 (Korean Cell Line Bank
[KCLB], Seoul, Korea) were maintained in RPMI-1640 supple-
mented with 10% FBS. The detailed information of these cell lines
were listed in Table S1. Both HDAC1-specific and scrambled
siRNA (negative control) were purchased from Genolution
(Genolution Pharmaceuticals, Inc, Seoul, Korea) (Table S2).
LC3B specific and negative control siRNA were synthesized
(BIONEER Corp., Daejeon, Korea) (Table S2). Cells were
transfected with siRNA using Lipofectamine
TM 2000 (Invitrogen,
San Diego, CA, USA) in accordance with the manufacturer’s
instructions.
Plasmid preparation
The minimal luciferase reporter plasmid is Sp1-luc [36]. pWWP
was generated by subcloning the 2.4 kbp human wild-type
p21
WAF1/Cip1 promoter into pGL3-Basic reporter vector, and
three deletion-formed plasmids (pWPdel-BstXI, pWP101 and
pWPdel-SmaI) and two mutant plasmids which have mutation on
specific Sp1 binding site (pWPmt-Sp1-3 and pWPmt-Sp1-5,6)
[36]. The HDAC1 shRNA and scrambled shRNA template oligos
were synthesized and cloned into pSilencer 3.1-H1 neo plasmid
(Ambion, Austin, TX, USA). Two pairs of oligonucleotide
sequences for the templatd of shRNA vectors were listed in Table
S3.
MTT assay
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) assay was conducted to measure the number of viable cells.
At the indicated time point, medium was replaced with the fresh
medium containing 0.5 mg/mL of MTT (Sigma-Aldrich, St.
Louis, MO, USA). After 4 h incubation at 37uC, the cellular
formazan product was dissolved in dimethylsulfoxide (DMSO),
and the absorbance was measured at a wavelength of 570 nm by
using spectrophotometry (PerkinElmer Inc, Boston, MA, USA).
Analysis of cell cycle distribution and apoptosis by flow
cytometry
Hep3B cells were transfected with either HDAC1 siRNA (si-
HDAC1) or scrambled siRNA (si-Scr) in 60-mm dishes. After 48 h
incubation, transfected cells were collected and washed twice with
PBS. Subsequently, cells were fixed in 70% ethanol overnight at
220uC. Fixed cells were then washed once in ice-cold PBS and
stained with propidium iodide (PI) staining solution (50 mg/mL PI,
100 mg/mL RNase, 0.05% Triton X-100 in PBS). PI-stained cells
were then analyzed for their DNA content by using a
FACSCalibur flow cytometry with CellQuest
TM software (BD
Biosciences, San Jose, CA, USA). Annexin V-FITC kit (BD
Biosciences) was used to measure the percentage of apoptosis.
After 72 h post-transfection of HDAC1 siRNA, Hep3B cells were
harvested and resuspended in 100 mL of binding buffer (1610
6
cells/mL) containing 5 mL of Annexin V-FITC and 5 mL of PI.
After incubation away from light for 15 min at room temperature,
the stained cells were analyzed by FACSCalibur and FlowJo
software (Tree Star).
qRT-PCR
Total RNA was isolated by using TRIzol (Invitrogen) as
described by the manufacturer. cDNA was generated by
Transcriptor First Strand cDNA Synthesis Kit (Roche Applied
Science, Indianapolis, IN, USA). Relative levels of specific mRNA
were determined with a SYBR Green chemistry system. All PCRs
were performed with the iQ
TM5 Real-Time PCR Detection
System (Bio-Rad Laboratories, Philadelphia, PA, US) according to
the manufacturer’s instruction. The GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) gene was used as a control for
normalization. PCR primers used were listed in Table S4.
Western blot analysis
Cultured cells were washed with ice-cold PBS and cell lysates
were prepared in RIPA buffer (50 mM Tris-Cl pH 7.4, 150 mM
NaCl, 0.25% sodium deoxycholate, 1% NP-40, 100 mg/mL
PMSF, 16cØmplete Protease Inhibitor Cocktail (Roche Applied
Science, Indianapolis, IN, USA)). Cell lysates were passed through
1 mL needle syringe to facilitate the disruption of the cell
membranes and centrifuged at 14,000 rpm for 15 min at 4uC,
and supernatants were collected. Protein concentrations of cell
lysates were determined by PierceH BCA Protein Assay Kit
(Pierce, Rockford, IL, USA). Total protein was loaded onto an
SDS-PAGE gel and transferred onto polyvinylidene difluoride
(PVDF) membranes (Millipore). Membranes were blocked for 1 h
at room temperature in 5% skim milk, washed with TBST
(150 mM NaCl, 10 mM Tris pH 7.4, 0.1% Tween-20), and
incubated with the indicated antibodies (Table S5). Membranes
were washed three times in TBST and HRP-conjugated secondary
antibody was added at 1:5000 in 5% skim milk for 1 h at room
temperature. Membranes were washed and processed with ECL
Plus Western Blotting detection kit (Amersham Biosciences,
Buckinghamshire, UK) and the signal was detected using an
LAS-4000 image analyzer (Fuji Photo Film Co., Tokyo, Japan).
Protein level was quantified by ImagJ solftware.
ChIP-qPCR analysis
Cells were grown overnight in 100 mm dishes to 70–90%
confluence, then cross-linked with formaldehyde, harvested, and
chromatin immunoprecipitations were performed following the
protocol for ChIP-qPCR analysis as described in our previous
report [22]. For each IP, diluted chromatin was incubated with
antibodies specific for HDAC1, Ac-histone H3 and Ac-histone H4
(Table S5) or normal rabbit IgG at 4uC for 2 h or overnight. The
purified DNA was used as template for 60 cycles of PCR
amplification using designated primers (Table S4).
Luciferase reporter assay
The p21 promoter plasmids were transiently co-transfected into
Hep3B cells with HDAC1 siRNA or scrambled siRNA. Luciferase
activity was measured in a luminometer (Perkin Elmer Inc.) after
48 h post-transfection with Luciferase Reporter Assay System
(Promega, Madison, WI, USA). The luciferase activities were
normalized with the amount of protein in cell lysates.
shRNA (HDAC1 KD#1) were maintained in 6-well plates. The graph bar indicates the number of colonies. Data are presented as mean 6 SD from
three independent experiments (*p,0.05, HDAC1KD#1 vs Mock#1). (D) Overall tumor growth of Hep3B cell xenografts. (E) Mice were sacrificed at
eighty days after injection, and the tumor weight was measured. Data were presented as mean 6 SD (*p,0.05). (F) At the moment of sacrifice,
xenograft tumors were excised, and total protein extracted from five randomly selected mice of each group was subjected to Western blot analysis
using the indicated antibodies. The protein expressions were normalized to those of GAPDH, and the relative expression level of each protein was
depicted as bar graph (*p,0.05).
doi:10.1371/journal.pone.0034265.g006
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The Hep3B cells were grown on 6-well tissue culture plates and
transfected with either HDAC1 siRNA or scrambled siRNA.
Seventy-two hours after transfection, cells were fixed with 2%
glutaraldehyde in 0.1 M cacodylate with 3 mM CaCl2 at 4uC
overnight, and then fixed with 1% OsO4 for 60 min. Samples
were dehydrated through an ethanol series and transferred into
Epon resin. Ultrathin sections were cut with a diamond knife on a
Reichert ultra microtome; the sections were mounted on Formvar
single-hole grids or 150-mesh grids, stained with uranyl acetate
and lead citrate, and then examined at 80 kV under electron
microscope (JEOL JEM 1010).
Immunofluorescence
Cells were seeded on circular microscope cover slips (Fisher)
precoated with fibronectin (final concentration of 10 mg/mL) and
UV light sterilized. Slides were placed into 6-well tissue culture
plates (Falcon). After transfection of either HDAC1 or scrambled
siRNA for 72 h, cells were washed with PBS for 3 times and fixed
in 4% paraformaldehyde solution for 10 min at room tempera-
ture. After rinsing with PBS, the cells were permeabilized with
0.2% Triton X-100 for 10 min. Following another rinse with PBS,
cells were blocked for 1 h at room temperature with 4% BSA-PBS
solution. The LC3B antibody (concentration 1:100) was diluted in
blocking buffer and incubated at 4uC for overnight. The cover
slips were washed with PBS and incubated with Alexa FluorH 488-
conjugated anti-rabbit IgG (Invitrogen) (concentration 1:1000) for
1.5 h at room temperature. The cells were washed with PBS and
counterstained with Hoechst (Invitrogen) diluted at 1:10000.
Cover slips were mounted onto the glass slides using Gel/Mount
(Biomeda, Foster City, CA). All images were obtained using Zeiss
Axio Imager M1 microscope (Carl Zeiss MicroImaging GmbH,
Oberkochen, Germany).
Establishment of stable cell lines
Hep3B cells were transfected with either HDAC1 or scrambled
shRNA vector. Twenty four hours later, transfected cells were
subcultured at 1:10 dilution to new culture dishes. The culture
medium containing 0.5 mg/mL geneticin (Invitrogen) was
changed every 3 days for 2 to 3 weeks until colonies of resistant
cells formed.
In vivo tumor xenograft study
Six week-old athymic nude mice were housed in filter-topped
cages and received food and water ad labium. Tumors were
generated by subcutaneous injection (s.c.) into the right lower flank
with 5610
6 of Hep3B cells suspended in 100 mL PBS and mixed
with 20% matrigel. After five to seven weeks from the cell
inoculation, palpable tumours were established. Tumor dimen-
sions were measured two times per week with a caliper. Tumor
volumes were estimated as follows: V (mm
3)=(length6width
2)/2.
Tumor weights were recorded at the time of sacrifice in order to
evaluate HDAC1 knockdown response.
Colony forming assay
The established stable Hep3B cells were cultured in a 6-well
tissue culture plate at 1500 cells/well. Cells were grown for 10–14
days with geneticin at 0.5 mg/mL. Colonies were fixed by 4%
paraformaldehyde for 30 min and stained with 0.5 mL of 0.005%
Crystal Violet to enable enumeration of colonies. The colonies
were counted as reported before [37].
Statistical analysis
Unless otherwise stated, each experiment was performed at least
three times and all the values were expressed as mean 6 SD. The
differences between the groups were compared using Student’s t-
test. p,0.05 was considered statistically significant.
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